
Marcos Palatnik

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11332222/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine. Vaccine, 2004, 22, 2234-2243.	3.8	121

A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (Si $_{2}^{1/2}$ o) Tj ETQqQ 0 rgBT /Overlock

3	Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis. Vaccine, 2002, 21, 30-43.	3.8	98
4	Decrease of the incidence of human and canine visceral leishmaniasis after dog vaccination with Leishmune® in Brazilian endemic areas. Vaccine, 2009, 27, 3505-3512.	3.8	91
5	Haemolytic activities of plant saponins and adjuvants. Effect of Periandra mediterranea saponin on the humoral response to the FML antigen of Leishmania donovani. Vaccine, 1997, 15, 1024-1029.	3.8	84
6	Prevalence of Anti-Leishmania donovani Antibody Among Brazilian Blood Donors and Multiply Transfused Hemodialysis Patients. American Journal of Tropical Medicine and Hygiene, 1997, 57, 168-171.	1.4	67
7	lgG1/lgG2 antibody dichotomy in sera of vaccinated or naturally infected dogs with visceral leishmaniosis. Vaccine, 2003, 21, 2589-2597.	3.8	62
8	Leishmania donovani: titration of antibodies to the fucose-mannose ligand as an aid in diagnosis and prognosis of visceral leishmaniasis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1995, 89, 390-393.	1.8	49
9	Adaptive Immunity against Leishmania Nucleoside Hydrolase Maps Its C-Terminal Domain as the Target of the CD4+ T Cell–Driven Protective Response. PLoS Neglected Tropical Diseases, 2010, 4, e866.	3.0	48
10	Immunotherapy against murine experimental visceral leishmaniasis with the FML-vaccine. Vaccine, 2003, 21, 4668-4676.	3.8	44
11	Vaccination of Swiss Albino mice against experimental visceral leishmaniasis with the FML antigen of Leishmania donovani. Vaccine, 1999, 17, 2554-2561.	3.8	43
11	Vaccination of Swiss Albino mice against experimental visceral leishmaniasis with the FML antigen of Leishmania donovani. Vaccine, 1999, 17, 2554-2561. Vaccination of Balb/c mice against experimental visceral leishmaniasis with the GP36 glycoprotein antigen of Leishmania donovani. Vaccine, 2001, 19, 3104-3115.	3.8 3.8	43 43
	Leishmania donovani. Vaccine, 1999, 17, 2554-2561. Vaccination of Balb/c mice against experimental visceral leishmaniasis with the GP36 glycoprotein		
12	Leishmania donovani. Vaccine, 1999, 17, 2554-2561. Vaccination of Balb/c mice against experimental visceral leishmaniasis with the GP36 glycoprotein antigen of Leishmania donovani. Vaccine, 2001, 19, 3104-3115. A Chimera Containing CD4+ and CD8+ T-Cell Epitopes of the Leishmania donovani Nucleoside Hydrolase (NH36) Optimizes Cross-Protection against Leishmania amazonesis Infection. Frontiers in Immunology,	3.8	43
12 13	Leishmania donovani. Vaccine, 1999, 17, 2554-2561. Vaccination of Balb/c mice against experimental visceral leishmaniasis with the GP36 glycoprotein antigen of Leishmania donovani. Vaccine, 2001, 19, 3104-3115. A Chimera Containing CD4+ and CD8+ T-Cell Epitopes of the Leishmania donovani Nucleoside Hydrolase (NH36) Optimizes Cross-Protection against Leishmania amazonesis Infection. Frontiers in Immunology, 2017, 8, 100. Improving methods for epidemiological control of canine visceral leishmaniasis based on a mathematical model. Impact on the incidence of the canine and human disease. Anais Da Academia	3.8 4.8	43 35
12 13 14	 Leishmania donovani. Vaccine, 1999, 17, 2554-2561. Vaccination of Balb/c mice against experimental visceral leishmaniasis with the CP36 glycoprotein antigen of Leishmania donovani. Vaccine, 2001, 19, 3104-3115. A Chimera Containing CD4+ and CD8+ T-Cell Epitopes of the Leishmania donovani Nucleoside Hydrolase (NH36) Optimizes Cross-Protection against Leishmania amazonesis Infection. Frontiers in Immunology, 2017, 8, 100. Improving methods for epidemiological control of canine visceral leishmaniasis based on a mathematical model. Impact on the incidence of the canine and human disease. Anais Da Academia Brasileira De Ciencias, 2004, 76, 583-593. Cross-Protective Immunity to Leishmania amazonesis is Mediated by CD4+ and CD8+ Epitopes of 	3.8 4.8 0.8	43 35 35
12 13 14 15	 Leishmania donovani. Vaccine, 1999, 17, 2554-2561. Vaccination of Balb/c mice against experimental visceral leishmaniasis with the GP36 glycoprotein antigen of Leishmania donovani. Vaccine, 2001, 19, 3104-3115. A Chimera Containing CD4+ and CD8+ T-Cell Epitopes of the Leishmania donovani Nucleoside Hydrolase (NH36) Optimizes Cross-Protection against Leishmania amazonesis Infection. Frontiers in Immunology, 2017, 8, 100. Improving methods for epidemiological control of canine visceral leishmaniasis based on a mathematical model. Impact on the incidence of the canine and human disease. Anais Da Academia Brasileira De Ciencias, 2004, 76, 583-593. Cross-Protective Immunity to Leishmania amazonensis is Mediated by CD4+ and CD8+ Epitopes of Leishmania donovani Nucleoside Hydrolase Terminal Domains. Frontiers in Immunology, 2014, 5, 189. Leishmania donovani Nucleoside Hydrolase (NH36) Domains Induce T-Cell Cytokine Responses in Human 	3.8 4.8 0.8 4.8	43 35 35 31

#	Article	IF	CITATIONS
19	The Leishmune®Ì s Nucleoside hydrolase DNA vaccine as an aid in immunotherapy of canine visceral leishmaniasis. Procedia in Vaccinology, 2012, 6, 64-73.	0.4	13
20	Resistance to visceral leishmaniasis is severely compromised in mice deficient of bradykinin B2-receptors. Parasites and Vectors, 2012, 5, 261.	2.5	13